Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living ...
Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated bleeds Bagsværd, Denmark, 7 February 2025 - Novo ...